Terms ending in 2030
Every in-force patent on CSL Behring GmbH's record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,632,773 | Antibody Composition with Altered Fab Sialylation In force · High confidence | CSL Behring AG | In force | High confidence | |
| US 8,603,979 | Von Willebrand Factor or Factor VIII and Von Willebrand Factor for the Treatment of Coagulopathy Induced by Inhibitors of Thrombocytes In force · High confidence | CSL Behring GmbH | In force | High confidence | |
| US 7,939,632 | Proteolytically Cleavable Fusion Proteins with High Molar Specific Activity In force · High confidence | CSL Behring GmbH | In force | High confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.